PROTON-PUMP INHIBITORS REDUCE RISK OF GASTROINTESTINAL EVENTS REGARDLESS OF ASPIRIN DOSE IN PATIENTS REQUIRING DUAL ANTIPLATELET THERAPY: INSIGHTS FROM THE COGENT TRIAL

Background The COGENT trial showed that proton-pump inhibitors (PPIs) safely reduced rates of gastrointestinal (GI) events in patients requiring dual antiplatelet therapy (DAPT).

Saved in:
Bibliographic Details
Published inJournal of the American College of Cardiology Vol. 67; no. 13; p. 2100
Main Authors Vaduganathan, Muthiah, Bhatt, Deepak, Cryer, Byron L, Liu, Yuyin, Hsieh, Wen-Hua, Doros, Gheorghe, Cohen, Marc, Lanas, Angel, Schnitzer, Thomas J, Shook, Thomas, Lapuerta, Pablo, Goldsmith, Mark A, Laine, Loren, Cannon, Christopher
Format Journal Article
LanguageEnglish
Published New York Elsevier Inc 05.04.2016
Elsevier Limited
Subjects
Aspirin
Cardiology
Cardiovascular
Heart attacks
Internal Medicine
Online AccessGet full text

Cover

More Information
Summary:Background The COGENT trial showed that proton-pump inhibitors (PPIs) safely reduced rates of gastrointestinal (GI) events in patients requiring dual antiplatelet therapy (DAPT).
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(16)32101-5